Company Filing History:
Years Active: 2025
Title: Miechaleen Diers: Innovator in Gene Editing Technology
Introduction
Miechaleen Diers is a prominent inventor based in Minneapolis, MN (US). He has made significant contributions to the field of gene editing, particularly in the area of lymphohematopoietic engineering. His innovative work has the potential to impact therapeutic applications in immunotherapy.
Latest Patents
Miechaleen Diers holds a patent for "Lymphohematopoietic engineering using CAS9 base editors." This patent outlines methods and systems for targeted gene disruption and targeted gene knock-in in mammalian cells. The technology utilizes base editors and guide RNAs (gRNAs) designed to target splice acceptor-splice donor sites. Additionally, the patent describes genetically engineered cells with targeted disruptions in immunotherapy-related genes, which include a CAR/TCR for therapeutic applications. He has 1 patent to his name.
Career Highlights
Miechaleen Diers is affiliated with the University of Minnesota, where he conducts research and develops innovative solutions in gene editing. His work is at the forefront of advancing genetic engineering techniques, which are crucial for developing new therapies.
Collaborations
Miechaleen collaborates with notable colleagues, including Branden Moriarity and Beau R Webber. Their combined expertise enhances the research and development efforts in their field.
Conclusion
Miechaleen Diers is a key figure in the realm of gene editing, with a focus on innovative methods that could revolutionize immunotherapy. His contributions are paving the way for future advancements in genetic engineering.